Posterior Polymorphous Corneal Dystrophy

Back

Background

First described by Koeppe, posterior polymorphous corneal dystrophy (PPMD) is a dominantly inherited condition characterized by particular alterations of the Descemet membrane and the corneal endothelium.[1] Typically, the corneal changes are either slowly progressive or nonprogressive. In severe cases, corneal decompensation and edema can occur. Although PPMD is most often a bilateral condition, marked asymmetry in the degree of involvement may be seen. Most persons with PPMD are asymptomatic. See the image below.



View Image

Slit lamp image demonstrates posterior corneal vesicles and opacities in linear bands and other polymorphous configurations typical of posterior polym....

Pathophysiology

Three main abnormalities are described: vesicular changes, endothelial band lesions, and irregular diffuse opacities of the posterior corneal surface involving both the Descemet membrane and the endothelium. The corneal endothelium undergoes a transformation and demonstrates many epithelial characteristics on examination with electron microscopy and immunohistochemical analysis. Often, the endothelium is found to be multilayered. Most patients exhibit vesicular lesions, which are the hallmark of PPMD.

Epidemiology

Frequency

United States

The frequency of PPMD is not well documented. Although it is considered to be uncommon, PPMD may be recognized and diagnosed more often in recent years than in the past.

International

Liskova et al found that the prevalence of PPCD in the Czech Republic appears to be the highest worldwide.[2]

Mortality/Morbidity

The effect of PPMD on patients is highly variable, with a broad clinical spectrum of findings, ranging from nonprogressive asymptomatic disease to progressive or advanced debilitating corneal disease with corneal decompensation and glaucoma.

Race

No racial predilection exists.

Sex

No sexual predilection exists.

Age

Although PPMD is an autosomal dominantly inherited corneal dystrophy, the age at diagnosis is highly variable because of the broad spectrum of disease severity. Findings may be present at birth. Most patients are first identified at age 30-50 years; however, this is likely only indicative of a more common age for ocular examinations.

Some patients may present at birth with congenital disease, exhibiting advanced disease with corneal edema.

Presentation in adulthood is indicative of a more stable disease state with a decreased probability of progression to corneal decompensation.

Most patients with significant symptoms present at age 25-50 years.

History

The clinical findings in patients with PPMD are highly variable, with a broad clinical spectrum of findings, ranging from only occasional Descemet membrane vesicles to progressive debilitating corneal disease with corneal decompensation and glaucoma.

A family history of PPMD should be assessed.

Although most patients with PPMD are asymptomatic, the most common symptoms in those with more significant involvement are as follows:

Physical

The most characteristic finding on slit lamp biomicroscopy is multiple vesicles or blisters, either isolated or grouped in clusters, on the posterior corneal surface. The vesicles often have identifiable surrounding grayish halos. These are often at the level of Descemet membrane and the endothelium, but they can also be seen in the posterior stroma.

Slit lamp biomicroscopy may also identify all or some of the following characteristics depending on the extent of the disease:

Causes

The precise etiology of PPMD remains unknown. PPMD is a congenital inherited dystrophy involving abnormalities of the corneal endothelium and the Descemet membrane.[3, 4]

Most cases of PPMD are transmitted in an autosomal dominant fashion with variable expression, although autosomal recessive transmission has also been reported.

A number of autosomal dominant cases of PPMD have been linked to a mutation in an unidentified gene located at band 20q11, whereas other cases have reported a mutation in a gene encoding for collagen VIII located on chromosome 1 (COL8A2) as the cause of PPMD.

In other cases, the genetic locus remains unknown.

PPMD has been associated with other conditions, including the following:

Laboratory Studies

No lab studies are available.

Imaging Studies

Specular microscopy has proven to be valuable in identifying the characteristic vesicular changes of the Descemet membrane in patients with PPMD. Typically, the endothelial cell count is only mildly diminished with varying amounts of polymegethism and pleomorphism.

Confocal microscopy has also been used to identify the typical features of PPMD.[5]

On most occasions, PPMD can be clinically diagnosed using slit lamp examination; however, mild cases may require further imaging studies to confirm the diagnosis.

Other Tests

Tonometry is used to measure intraocular pressure, which may be elevated in up to 40% of patients with PPMD.

The secondary open-angle glaucoma that occurs in some patients with PPMD is believed to be due to an abnormality of the trabecular endothelium.

Examination of family members may also be helpful in making the diagnosis.

Histologic Findings

Light microscopy typically demonstrates 4 types of cells: normal endothelial cells, degenerated endothelial cells, fibroblast-like cells, and epithelial-like cells. In 60% of cases, a multilayered endothelium can be identified that has many characteristics similar to that of the epithelium. Immunohistochemical studies have also shown positive staining of the endothelium using epithelial cell markers.

Scanning electron microscopy and transmission electron microscopy of corneal tissue show lamination of the Descemet membrane, fibroblast-like endothelial cells, and microvilli characteristic of epithelial transformation of the corneal endothelium.

Staging

No formal staging system has been described for PPMD.

Medical Care

Management of PPMD varies widely based on the differences in severity of corneal decompensation. Many patients who are asymptomatic and show minimal signs of PPMD can be treated conservatively and do not require therapy.

Ruptured corneal bullae should be treated similar to a corneal abrasion.

Hyperosmotic saline drops and ointments may be used in cases of corneal failure with corneal edema.

Secondary glaucoma may require medical or surgical management.

A bandage soft contact lens may be used as a temporary measure to treat bullous keratopathy.

Surgical Care

The risk factors for more advanced disease, requiring surgery, include increased intraocular pressure and iridocorneal adhesions.

Corneal transplantation is usually reserved for patients with substantially decreased visual acuity or when the disease is advanced and painful due to ruptured epithelial bullae. Penetrating keratoplasty (full thickness corneal transplantation) has been the transplant procedure of choice in the past. The newer techniques of posterior endothelial keratoplasty, such as Descemet membrane stripping endothelial keratoplasty (DSEK) and Descemet membrane endothelial keratoplasty (DMEK), have been shown to be successful.[6, 7]

Rare cases of corneal graft failure due to recurrence of PPMD in the donor graft have been reported, but the most common problem following a corneal transplant is related to uncontrolled glaucoma.[8]

To treat pain in eyes without good visual potential, other procedures, such as anterior stromal micropuncture, excimer laser phototherapeutic keratectomy, amniotic membrane transplantation, and conjunctival flap surgery, can also be considered.

When glaucoma medications no longer adequately control the intraocular pressure, glaucoma laser or incisional surgery may be required to prevent glaucomatous optic nerve damage. Surgery with limited success is often seen in patients with peripheral anterior synechiae without gonioscopy and elevated intraocular pressure. Poor intraocular pressure control, even with surgical intervention, is observed.

Consultations

Depending on the severity of the condition, consultation with corneal and glaucoma subspecialists may be warranted.

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Sodium chloride hypertonic, ophthalmic (Muro 128 Ophthalmic)

Clinical Context:  Used for temporary relief of corneal edema. Available as 2% and 5% ophthalmic solution concentrations and 5% ointment.

Class Summary

Sodium chloride hypertonic ophthalmic solutions are used to dehydrate the cornea.

Further Outpatient Care

The frequency of follow-up care for patients with PPMD depends on the severity of disease.

Complications

Corneal erosion, secondary corneal ulcers, corneal scarring, graft rejection, endothelial failure, and other complications can occur and lead to corneal graft failure.

Glaucoma can be present prior to corneal transplantation or may result from corneal transplantation.

Prognosis

The prognosis is generally dependent on the severity of disease. In most cases, PPMD is a slowly progressive or nonprogressive disease. Patients with mild disease that is identified in adulthood have the best prognosis and are unlikely to require penetrating keratoplasty during their lifetime.

Author

Mark Ventocilla, OD, FAAO, Adjunct Clinical Professor, Michigan College of Optometry; Editor, American Optometric Association Ocular Surface Society Newsletter; Chief Executive Officer, Elder Eye Care Group, PLC; Chief Executive Officer, Mark Ventocilla, OD, Inc; President, California Eye Wear, Oakwood Optical

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Christopher J Rapuano, MD, Professor, Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Hospital

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cornea Society, AAO, OMIC, Avedro; Bio-Tissue; GSK, Kala, Novartis; Shire; Sun Ophthalmics; TearLab<br/>Serve(d) as a speaker or a member of a speakers bureau for: Avedro; Bio-Tissue; Shire<br/>Received income in an amount equal to or greater than $250 from: AAO, OMIC, Avedro; Bio-Tissue; GSK, Kala, Novartis; Shire; Sun Ophthalmics; TearLab.

Chief Editor

Hampton Roy, Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Fernando H Murillo-Lopez, MD, Senior Surgeon, Unidad Privada de Oftalmologia CEMES

Disclosure: Nothing to disclose.

Acknowledgements

Dustin J Coupal, MD, FRCSC Eye Specialist and Surgeon, Private Practice

Dustin J Coupal, MD, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, Canadian Medical Association, Canadian Medical Protective Association, and Canadian Ophthalmological Society

Disclosure: Nothing to disclose.

W Keith Hamilton, MD Clinical Assistant Professor, Department of Ophthalmology, Saskatoon City Hospital Eye Centre

Disclosure: Nothing to disclose.

References

  1. Koeppe L. Klinische Beobachtungen mit der Nerstspaltlampe und dem Hornhautmikroskop. Albrecht von Graefe's Arch Klin Exp Ophthalmol. 1916. 91:375-379.
  2. Liskova P, Gwilliam R, Filipec M, Jirsova K, Reinstein Merjava S, Deloukas P, et al. High prevalence of posterior polymorphous corneal dystrophy in the czech republic; linkage disequilibrium mapping and dating an ancestral mutation. PLoS One. 2012. 7(9):e45495. [View Abstract]
  3. Liskova P, Palos M, Hardcastle AJ, Vincent AL. Further genetic and clinical insights of posterior polymorphous corneal dystrophy 3. JAMA Ophthalmol. 2013 Oct. 131(10):1296-303. [View Abstract]
  4. Bakhtiari P, Frausto RF, Roldan AN, Wang C, Yu F, Aldave AJ. Exclusion of pathogenic promoter region variants and identification of novel nonsense mutations in the zinc finger E-box binding homeobox 1 gene in posterior polymorphous corneal dystrophy. Mol Vis. 2013. 19:575-80. [View Abstract]
  5. Bozkurt B, Irkec M, Mocan MC. In vivo confocal microscopic findings in posterior polymorphous corneal dystrophy. Cornea. 2013 Sep. 32(9):1237-42. [View Abstract]
  6. Bromley JG, Randleman JB, Stone D, Stulting RD, Grossniklaus HE. Clinicopathologic findings in iridocorneal endothelial syndrome and posterior polymorphous membranous dystrophy after Descemet stripping automated endothelial keratoplasty. Cornea. 2012 Sep. 31(9):1060-4. [View Abstract]
  7. Studeny P, Jirsova K, Kuchynka P, Liskova P. Descemet membrane endothelial keratoplasty with a stromal rim in the treatment of posterior polymorphous corneal dystrophy. Indian J Ophthalmol. 2012 Jan-Feb. 60(1):59-60. [View Abstract]
  8. Merjava S, Malinova E, Liskova P, Filipec M, Zemanova Z, Michalova K, et al. Recurrence of posterior polymorphous corneal dystrophy is caused by the overgrowth of the original diseased host endothelium. Histochem Cell Biol. 2011 Jul. 136(1):93-101. [View Abstract]
  9. Moshirfar M, Barsam CA, Tanner MC. Laser in situ keratomileusis in patients with posterior polymorphous dystrophy. Cornea. 2005 Mar. 24(2):230-2. [View Abstract]
  10. Todo et al. Photorefractive keratectomy in posterior polymorphous dystrophy; abstract presented at ASCRS 2010.
  11. Anderson NJ, Badawi DY, Grossniklaus HE, Stulting RD. Posterior polymorphous membranous dystrophy with overlapping features of iridocorneal endothelial syndrome. Arch Ophthalmol. 2001 Apr. 119(4):624-5. [View Abstract]
  12. Bechara SJ, Grossniklaus HE, Waring GO, Wells JA 3rd. Keratoconus associated with posterior polymorphous dystrophy. Am J Ophthalmol. 1991 Dec 15. 112(6):729-31. [View Abstract]
  13. Boruchoff SA, Weiner MJ, Albert DM. Recurrence of posterior polymorphous corneal dystrophy after penetrating keratoplasty. Am J Ophthalmol. 1990 Mar 15. 109(3):323-8. [View Abstract]
  14. Brooks AM, Grant G, Gillies WE. Differentiation of posterior polymorphous dystrophy from other posterior corneal opacities by specular microscopy. Ophthalmology. 1989 Nov. 96(11):1639-45. [View Abstract]
  15. Chiou AG, Kaufman SC, Beuerman RW, et al. Confocal microscopy in posterior polymorphous corneal dystrophy. Ophthalmologica. 1999. 213(4):211-3. [View Abstract]
  16. Colville DJ, Savige J. Alport syndrome. A review of the ocular manifestations. Ophthalmic Genet. 1997 Dec. 18(4):161-73. [View Abstract]
  17. Krachmer, Mannis, Holland, eds. Cornea. 1997. Volume II: 1063-73.
  18. Grupcheva CN, Chew GS, Edwards M, et al. Imaging posterior polymorphous corneal dystrophy by in vivo confocal microscopy. Clin Experiment Ophthalmol. 2001 Aug. 29(4):256-9. [View Abstract]
  19. Henriquez AS, Kenyon KR, Dohlman CH, et al. Morphologic characteristics of posterior polymorphous dystrophy. A study of nine corneas and review of the literature. Surv Ophthalmol. 1984 Sep-Oct. 29(2):139-47. [View Abstract]
  20. Klintworth GK. The molecular genetics of the corneal dystrophies--current status. Front Biosci. 2003 May 1. 8:d687-713. [View Abstract]
  21. Krachmer JH. Posterior polymorphous corneal dystrophy: a disease characterized by epithelial-like endothelial cells which influence management and prognosis. Trans Am Ophthalmol Soc. 1985. 83:413-75. [View Abstract]
  22. Laganowski HC, Sherrard ES, Muir MG, Buckley RJ. Distinguishing features of the iridocorneal endothelial syndrome and posterior polymorphous dystrophy: value of endothelial specular microscopy. Br J Ophthalmol. 1991 Apr. 75(4):212-6. [View Abstract]
  23. Moroi SE, Gokhale PA, Schteingart MT, et al. Clinicopathologic correlation and genetic analysis in a case of posterior polymorphous corneal dystrophy. Am J Ophthalmol. 2003 Apr. 135(4):461-70. [View Abstract]
  24. Presberg SE, Quigley HA, Forster RK, Green WR. Posterior polymorphous corneal dystrophy. Cornea. 1985-86. 4(4):239-48. [View Abstract]
  25. Teekhasaenee C, Nimmanit S, Wutthiphan S, et al. Posterior polymorphous dystrophy and Alport syndrome. Ophthalmology. 1991 Aug. 98(8):1207-15. [View Abstract]
  26. Weissman BA, Ehrlich M, Levenson JE, Pettit TH. Four cases of keratoconus and posterior polymorphous corneal dystrophy. Optom Vis Sci. 1989 Apr. 66(4):243-6. [View Abstract]

Slit lamp image demonstrates posterior corneal vesicles and opacities in linear bands and other polymorphous configurations typical of posterior polymorphous corneal dystrophy.

Slit lamp image demonstrates posterior corneal vesicles and opacities in linear bands and other polymorphous configurations typical of posterior polymorphous corneal dystrophy.